Clinical efficacy of aspirin combined with clopidogrel in treating cerebral infarction and its effect on serum hs-CRP, sICAM-1 and TNF-α

Li, Min; Wang, Jing; Wang, Xinhong; Li, Guojie

doi:10.3892/etm.2019.8275

Cited by 11 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSVD is an intracranial small vessel lesion in sites such as arterioles, small veins, and capillaries caused by a combination of factors, which damages the white matter and gray matter in depth of brain and finally leads to a series of pathological and neuroimaging changes, thereby resulting in cognitive impairment and other clinical syndromes in patients [13]. Studies have confirmed [14] that CSVD is not only related to vascular cognitive dysfunction but also to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD), and as these two diseases are overlapped to some extent, most AD patients have signs of CSVD, including cognitive dementia, progressive cognitive decline, bladder sphincter dysfunction, and mental disorders [15]. Currently, there is no consensus on CSVD pathogenesis, but it may be due to the fact that chronic progressive subclinical ischemia in the brain increases vascular permeability, causing extravasation of intravascular substances, disruption of the blood-brain barrier, local inflammatory response, and then resulting in vascular and perivascular tissue damage [16].…”

Section: Discussionmentioning

confidence: 99%

Correlation of Serum C‐Peptide, Soluble Intercellular Adhesion Molecule‐1, and NLRP3 Inflammasome‐Related Inflammatory Factor Interleukin‐1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease

Yang

Wang

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. To explore the correlation of serum c-peptide, soluble intercellular adhesion molecule-1 (sICAM-1), and NLRP3 inflammasome-related inflammatory factor interleukin-1β (IL-1β) after brain magnetic resonance imaging (MRI) examination with cerebral small vessel disease (CSVD). Methods. A total of 72 CSVD patients treated in our hospital from December 2018 to December 2019 were selected as the case group and another 72 patients who presented cerebrovascular risk factors but obtained normal brain MRI examination result in the same period were selected as the control group. The serum specimen of patients in the two groups were collected, their serum c-peptide levels were measured by radio immunoassay, and their serum sICAM-1 and NLRP3 inflammasome-related inflammatory factor IL-1β were measured by enzyme-linked immunosorbent assay (ELISA), so as to analyze the correlation between these indicators and CSVD. Results. Compared with the control group, the level values of serum c-peptide, sICAM-1, and IL-1β were significantly higher in the case group ( P < 0.001 ), with CSVD being the dependent variable, and age, smoking, uric acid, history of stroke, serum c-peptide, sICAM-1, and IL-1β being the independent variables. A logistic regression analysis was conducted, and the result showed that age, smoking, serum c-peptide, sICAM-1, and IL-1β were the risk factors for CSVD, and by drawing the ROC curves, it could be concluded that the area under sICAM-1 curve was larger than that of other single indicator. Conclusion. Elevation of level values of serum c-peptide, sICAM-1, and NLRP3 inflammasome-related inflammatory factor IL-1β is correlative with CSVD, and age, smoking, serum c-peptide, sICAM-1, and IL-1β are the independent risk factors for CSVD.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation of Serum C‐Peptide, Soluble Intercellular Adhesion Molecule‐1, and NLRP3 Inflammasome‐Related Inflammatory Factor Interleukin‐1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease

Yang

Wang

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…For example, Fukuuchi et al [8] thought that clopidogrel was the first choice for treating noncardiac embolic cerebral infarction. Li et al [9] proposed that clopidogrel could improve the efficacy of aspirin in the treatment of ACI. Cerebral ischemia induces an increase in free radicals, which brings about ischemic brain damage such as edema and neuropathy [10].…”

Section: Introductionmentioning

confidence: 99%

Edaravone Combined with Clopidogrel Is Beneficial to Improve Efficacy, Neurological Impairment, and Life Function in Acute Cerebral Infarction Patients

Sun

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This research aimed at investigating the efficacy of edaravone combined with clopidogrel on acute cerebral infarction (ACI) and its influence on the neurological deficit and life function. Methods. Totally, 154 ACI cases were included and then divided into the control group (CG) (n = 71) and research group (RG) (n = 83) according to the treatment methods. Patients in the CG were treated with clopidogrel alone, and those in the RG were under edaravone-clopidogrel combination therapy. The efficacy, adverse reactions, NIHSS score, cerebral hemodynamic indexes, and Fugl-Meyer scale (FMA) and Barthel index (BI) of activities of daily living (ADL) scores were observed. Results. Compared with before treatment, the symptoms of both groups were improved after treatment: the NIHSS scores decreased, FMA and ADL scores increased, and cerebral hemodynamic indexes were improved. Compared with the CG, the efficacy and cerebral hemodynamic indexes of the RG were better, the adverse reactions were equivalent, the NIHSS score was lower, and the ADL and FMA scores were higher. Conclusion. Edaravone combined with clopidogrel can effectively treat ACI and improve the neurological deficit and life function of patients.

show abstract

“…A study has verified that inflammatory response is one of the important pathophysiological mechanisms of acute ischemic stroke, 22 and TNF-α, IL-6, and hs-CRP are important inflammatory mediators of secondary brain injuries in patients with acute ischemic stroke. This study analyzed the serum levels of inflammatory factors before and after treatment.…”

Section: Discussionmentioning

confidence: 97%

Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction

Gao

Zhang²,

Wo³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. Methods: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital between June 2018 and June 2019. They were randomly divided into two groups. The control group (70 cases) was treated with urokinase intravenous thrombolysis, and the observation group (70 cases) was given alteplase intravenous thrombolytic therapy. The treatment efficacy and safety of the two groups were compared. Results: The total effective rate of the observation group was 95.7%, and that of the control group was 78.6%, i.e., the total effective rate of the observation group was significantly superior to the that of the control group (P < 0.05). After treatment, the observation group had significantly lower National Institutes of Health Stroke Scale (NIHSS) score and significantly higher mini-mental state examination (MMSE) score than the control group; the difference was statistically significant (P<0.05). After treatment, the levels of inflammatory factors of both groups significantly decreased compared to before treatment, and the decrease in the observation group was larger than that in the control group (P<0.05). The levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) in the observation group were significantly lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The incidence of hemorrhagic adverse reaction in the observation group was lower than that in the control group (P<0.05). Conclusion: In the treatment of acute cerebral infarction, ccompared with urokinase, alteplase can further relieve cognitive impairment and promote the recovery of nerve function through inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1. doi: https://doi.org/10.12669/pjms.38.3.4521 How to cite this:Gao L, Zhang S, Wo X, Shen X, Tian Q, Wang G. Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction. Pak J Med Sci. 2022;38(3):---------. doi: https://doi.org/10.12669/pjms.38.3.4521 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Clinical efficacy of aspirin combined with clopidogrel in treating cerebral infarction and its effect on serum hs-CRP, sICAM-1 and TNF-α

Cited by 11 publications

References 18 publications

Correlation of Serum C‐Peptide, Soluble Intercellular Adhesion Molecule‐1, and NLRP3 Inflammasome‐Related Inflammatory Factor Interleukin‐1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease

Correlation of Serum C‐Peptide, Soluble Intercellular Adhesion Molecule‐1, and NLRP3 Inflammasome‐Related Inflammatory Factor Interleukin‐1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease

Edaravone Combined with Clopidogrel Is Beneficial to Improve Efficacy, Neurological Impairment, and Life Function in Acute Cerebral Infarction Patients

Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction

Contact Info

Product

Resources

About